Given all these data, our proposal involves initiating a phase I/II study, incorporating a safety run-in phase, to assess both the tolerability and efficacy of 177Lu-PSMA-1 in individuals diagnosed with PSMA-positive metastatic ccRCC, identified through 68Ga-PSMA PET as define below. This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.